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SI N C E August 1979, 18 segmental pan-creas transplantations in 17 diabetic 
recipients with end-stage renal failure have 
been performed at our institution (17 com-
bined pancreatic and renal allotransplanta-
tions, one pancreatic retransplantation). The 
course and outcome of simultaneous pan-
creatic and renal transplantations in the first 
three patients receiving conventional immu-
nosuppressive therapy have been published 
elsewhere.1"3 This article presents our experi-
ence with 13 segmental pancreatic allotrans-
plantations in 12 patients treated with the new 
immunosuppressive agent cyclosporine (San-
dimmune, Sandoz Ltd. , Basel, Switzerland). 
As details of patient selection, postoperative 
management, and long-term follow-up are 
presented by our group elsewhere in this 
issue,4,5 we will mainly concentrate on surgical 
aspects in this report. 
MATERIALS AND METHODS 
Twelve type I diabetic patients in end-stage renal 
failure (aged 25 to 49 years) have been accepted for 
treatment. Combined pancreatic and renal allotransplan-
tation was performed in all 12 patients, pancreatic 
retransplantation alone in one patient. 
Donor Pancreatectomy 
The technique of pancreas harvesting has been 
described previously.2 Recently, we modified our tech-
nique slightly: (1) Hypothermic in situ perfusion of the 
pancreas with Euro-Collins' solution was provided by an 
intraaortally situated catheter via the celiac axis. (2) The 
celiac axis, including an aortal patch and the portal vein, 
respectively, were used for anastomosis exclusively. Har-
vesting of the pancreas was combined with the removal of 
the kidneys (all cases), the removal of the heart (three 
cases), and the removal of heart/lung (one case). Organ 
harvesting was performed either at our own clinic or at 
external hospitals. Transportation of the organs was 
provided by helicopters or emergency cars. Cold ischemia 
time never exceeded five and one half hours. 
Special Donor Criteria 
Special donor criteria for pancreas harvesting were 
used at our institution: age, 15 to 40 years; stable circula-
tion; blood sugar and serum amylase, normal/subnormal; 
no obesity; negative crossmatch; and blood group compat-
ibility. 
Duct Obliteration 
The duct obliteration procedure was started immedi-
ately before transplantation; under hypothermic in vitro 
conditions, the duct was cannulated (Abbocath cannula). 
Between 3.5 and 6 mL of Ethibloc (prolamine, alcoholic 
amino acid solution) were injected throughout the ductal 
system under x-ray control. Duct obliteration was consid-
ered to be efficient when first signs of overinjection 
appeared as revealed by x-ray. After occlusion, the ductal 
orifice, as well as the parenchyma near the cut surface, 
were ligated. 
Recipient Operation 
Our technique of pancreatic transplantation has been 
slightly modified recently. The segmental pancreas graft 
was situated (in an upside-down position) extraperito-
neally in the right iliac fossa by positioning the distal 2/3 
intraperitoneally. Circulation was established by end-
to-side anastomosis of the portal vein to the right external 
iliac vein and the celiac axis (plus patch) to the right 
external iliac artery. The wound was drained for two to 
four days either by a silicon rubber drain or Penrose drain 
(Fig. 1). Following closure of this wound, a renal graft 
from the same donor was placed in the left iliac fossa 
using the standard technique. 
Immunosuppressive Protocol 
Basic immunosuppression consisted of intravenous 
(IV) cyclosporine 3.5 to 5 mg/kg/d over the first ten days 
posttransplant. Cyclosporine was administered orally (15 
mg/kg) until the end of one month, when it was decreased 
From the Transplantation Center, Department of Sur-
gery, Klinikum Grosshadern, and the Department of 
Internal Medicine "Innenstadt," University of Munich. 
Address reprint requests to Professor Dr W. Land, 
Department of Surgery, Klinikum Grosshadern, Mar-
chioninistr 15, DS000 München 70, FRG. 
© 1984 by Grune & St ration, Inc. 
0041-1345/84/1603~0044$03.00/0 
Transplantation Proceedings, Vol. XVI, No. 3 (June), 1984 729 
730 LAND ET AL 
Fig. 1. Technique recently used in segmental pan­
creatic transplantation: partially extra/interperitoneal 
position of the graft. For anastomosis, the portal vein as 
well as the celiac axis (plus an aortal patch) are used. 
The operation is done at the right iliac fossa. 
by 2 mg/kg monthly to a maintenance level of 6 to 8 
mg/kg monthly lo a maintenance level ol 6 to 8 mg/kg 
body wt. 
Steroids (methylprednisolone) were begun at 500 mg 
IV inlraoperatively by decreasing the daily dose to 30 mg 
Table 1. Results of Simultaneous Pancreatic and Renal 
Transplantation Under Cyclosporine Therapy 
(12 Patients) 
Patients in the 
Consecutive Series 
Survival Time (mo) 
(age) Pancreas Kidney Patient 
4. H. S . * (36 yr) (Venous thrombosis) 27 27 
5. P. K. (41 yr) 26 26 26 
6. A. B . (33 yr) 16 16 16 
7 . G . L . (26 yr) 6 6 6 
8. K. F. (49 yr) 1 1 
9. R. J . (25 yr) 2 
(Rejection) 
2 
(Rejection) 
6 
10. Η. K. (42 yr) 6 6 6 
11. F. S . (40 yr) 5 5 5 
12. U. S . (33 yr) 2 2 2 
13. S . K. (27 yr) (No function) 2 2 
14. M. S . (36 yr) 1.5 1.5 1.5 
15. G. S . (33 yr) 1 1 1 
during the first two weeks posttransplant. During the next 
two months, methylprednisolone was slowly decreased to 
a daily dose of 8 mg and maintained at that level. 
Antirejection treatment. Antirejection treatment 
consisted of three IV bolus injections of 500 mg methyl­
prednisolone during the first rejection episode. The sec­
ond and third rejection episodes were treated by adminis­
tration of antithymocyte globulin ( A T G , Fresenius, 
Frankfurt, F R G ) in a dose of 4 to 7.5 mg/kg daily over a 
period of seven days in combination with methylpredniso­
lone in a dose of 120 mg IV daily until reversal. 
RESULTS 
The overall results of 12 combined pan­
creatic and renal transplantations (and one 
pancreatic retransplantation) are shown in 
Table 1. One patient died of acute liver failure 
(acute yellow liver necrosis) posttransplant. 
The other patients are currently alive. Eight 
of 13 pancreatic grafts, as well as ten of 12 
renal grafts, are currently functioning (Au­
gust 1983); pancreatic grafts after 26, 16, 6, 6, 
5, 2, \ % and 1 month; renal grafts 27, 26, 16, 
6, 6, 5, 2, 2, l ' / 2 , and 1 month. Four of 13 
Table 2. Early (Local) Complications Following 
Simultaneous Organ Transplantation 
Complications 
•Retransplantation: second occurrence of venous throm­
bosis. 
f S e e Table 2, same patient. 
Patient Pancreas Kidney 
4. H. S. Venous throm­ None 
bosis (twice) 
5. P. K. Transient fistula Rupture after biopsy 
(led to operative re­
pair) 
6. A. B . Peripancreatic Wound hematoma (led 
fluid collec­ to evacuation) 
tion 
7. G. L . Transient fistula Wound hematoma (led 
to evacuation) 
8. K. F. None None 
9. R. J . Fistula; infection Rejection 
(rejection) 
10. Η. K. Peripancreatic None 
fluid collec­
tion 
11. F. S . Peripancreatic Wound hematoma (led 
fluid collec­ to evacuation) 
tion 
12. U. S. Transient fistula None 
13. S . K . No function: in­ Distal ureter necrosis 
fection (led to (led to operative re­
exploration) pair) 
14. M. S . Fistula None 
15. G. S . None None 
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pancreatic grafts failed because of acute irre-
versible vascular rejection,1 acute posttrans-
plant venous thrombosis,2 and no primary 
function.1 Concerning the last case, an abnor-
mal blood supply of the body and tail of the 
donor pancreas has to be discussed (only a few 
nutritive branches arising from the splenic 
artery without any parenchyma presentation 
were shown by angiography). We observed a 
relatively high incidence of early postopera-
tive local complications on both sites of the 
grafts as shown in Table 2. A t the site of the 
pancreatic graft, peripancreatic fluid collec-
tion requiring repeated needle aspiration and 
transient pancreatic fistula, respectively, were 
encountered most frequently; at the site of the 
renal graft, deep wound hematomas requiring 
surgical evacuation was observed. 
Rejection episodes of both organs proved to 
be almost mild under cyclosporine treatment. 
There was only one acute vascular-type rejec-
tion not responding to antirejection treatment. 
Normally, all rejection episodes could be 
reversed either by methylprednisolone (IV 
bolus) alone or by combined administration of 
methylprednisolone and A T C . 
DISCUSSION 
Our current technique of combined seg-
mental pancreatic and renal grafting using 
cyclosporine as posttransplant immunosup-
pressant has been associated with (1) low 
mortality, (2) an acceptable morbidity, (3) 
rare immunologic graft loss, (4) a relatively 
high incidence of early local complications, 
and (5) a reasonable rate of functioning pan-
creatic grafts (at the present time, August 
1983:61.5%). 
We assume and discuss that this high rate 
of functioning pancreatic grafts is primarily a 
result of the strong immunosuppressive 
potency of the new agent cyclosporine, which 
reduces the events of irreversible allograft 
rejection. This observation is in accordance 
with our results obtained in cadaveric renal 
transplantation using cyclosporine as basic 
immunosuppressive therapy; the one-year 
graft survival rate of renal allografts has 
improved by 20% (to 80%) compared with our 
historic controls using conventional immuno-
suppressive therapy.6 
The clinical use of cyclosporine may also 
have led to the low rate of mortality in our 
recent series, although other contributing fac-
tors, such as better selection and improved 
management of the patients, and the gaining 
of experience within the transplant group may 
play some role. 
The morbidity observed in our patients 
after combined transplantation certainly is 
higher than in kidney-transplanted patients 
but it seems acceptable. This morbidity 
mainly concerns the incidence of early local 
complications such as peripancreatic fluid col-
lection and transient pancreatic fistula at the 
site of the pancreatic graft, as well as severe 
wound hematomas at the site of the renal 
graft. 
Indeed, the incidence of complications from 
residual function of the exocrine system of the 
duct-occluded pancreatic graft worries us. We 
believe that these local complications proba-
bly arise from a too-early reabsorption of the 
occlusion substance E t h i b l o c ( R t h i c o n , R a r i -
tan, NJ) before the acini are completely atro-
phied (a decisive difference between Ethibloc 
and neoprene used by the Lyon group and 
others). I t is worthwhile to mention that the 
administration of somatostatin did not pre-
vent these local complications from arising 
from residual exocrine secretion. On the other 
hand, this property of early reabsorption may 
be the reason for the good long-term function 
of the pancreatic grafts as discussed by us 
elsewhere in this issue.4 I f it is suggested that a 
remaining foreign body causes increased 
fibrosis in the graft over a longer period of 
time, then the early reabsorption of ethibloc 
would imply a beneficial effect (as far as 
long-term function is concerned) because of a 
milder fibrosis-inducing effect. A completely 
intraperitoneal position of Ethibloc-occluded 
pancreatic grafts might reduce this kind of 
local complication. 
The incidence of wound hematoma at the 
site of the renal graft is obviously a result of 
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our aggressive regimen of early postoperative 
anticoagulation (heparinization). This proto-
col was applied to prevent venous thrombosis 
of the splenic vein of the pancreatic graft. In 
fact, this complication can be prevented com-
pletely by aggressive anticoagulation therapy 
according to our experience. Nevertheless, a 
new therapeutic concept of posttransplant 
anticoagulation is being worked out at the 
present time. 
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